JP2008535803A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535803A5 JP2008535803A5 JP2008501920A JP2008501920A JP2008535803A5 JP 2008535803 A5 JP2008535803 A5 JP 2008535803A5 JP 2008501920 A JP2008501920 A JP 2008501920A JP 2008501920 A JP2008501920 A JP 2008501920A JP 2008535803 A5 JP2008535803 A5 JP 2008535803A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- heterocyclyl
- cycloalkyl
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000003118 aryl group Chemical group 0.000 claims 40
- 125000000623 heterocyclic group Chemical group 0.000 claims 37
- 125000000217 alkyl group Chemical group 0.000 claims 36
- 125000001424 substituent group Chemical group 0.000 claims 21
- 125000000304 alkynyl group Chemical group 0.000 claims 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims 19
- 125000003342 alkenyl group Chemical group 0.000 claims 17
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 14
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 12
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 11
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 3
- 125000006664 (C1-C3) perfluoroalkyl group Chemical group 0.000 claims 3
- 125000005275 alkylenearyl group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 229910003849 O-Si Inorganic materials 0.000 claims 2
- 229910003872 O—Si Inorganic materials 0.000 claims 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 229910052710 silicon Inorganic materials 0.000 claims 2
- ZRMUHARFKVCBBD-UHFFFAOYSA-N 1-[3-(2,5-difluorophenyl)-5-[2-[hydroxy(dimethyl)silyl]ethyl]-5-phenyl-4h-pyrazol-1-yl]ethanone Chemical compound CC(=O)N1N=C(C=2C(=CC=C(F)C=2)F)CC1(CC[Si](C)(C)O)C1=CC=CC=C1 ZRMUHARFKVCBBD-UHFFFAOYSA-N 0.000 claims 1
- SQGUQPOZEZQJFQ-UHFFFAOYSA-N 1-[3-(2,5-difluorophenyl)-5-[4-[hydroxy(dimethyl)silyl]butyl]-5-phenyl-4h-pyrazol-1-yl]ethanone Chemical compound CC(=O)N1N=C(C=2C(=CC=C(F)C=2)F)CC1(CCCC[Si](C)(C)O)C1=CC=CC=C1 SQGUQPOZEZQJFQ-UHFFFAOYSA-N 0.000 claims 1
- DHGOBNDQUDJBND-LJAQVGFWSA-N 1-[4-[3-[(3s)-2-acetyl-5-(2-fluoro-5-trimethylsilylphenyl)-3-phenyl-4h-pyrazol-3-yl]propyl]piperazin-1-yl]ethanone Chemical compound C([C@]1(CC(=NN1C(=O)C)C=1C(=CC=C(C=1)[Si](C)(C)C)F)C=1C=CC=CC=1)CCN1CCN(C(C)=O)CC1 DHGOBNDQUDJBND-LJAQVGFWSA-N 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000010638 Kinesin Human genes 0.000 claims 1
- 108010063296 Kinesin Proteins 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 201000005264 laryngeal carcinoma Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 201000004962 larynx cancer Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 *C1(*)C(c2ccccc2)=NN(*)C1(*)c1ccccc1 Chemical compound *C1(*)C(c2ccccc2)=NN(*)C1(*)c1ccccc1 0.000 description 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66222605P | 2005-03-16 | 2005-03-16 | |
| PCT/US2006/008482 WO2006101761A2 (en) | 2005-03-16 | 2006-03-10 | Mitotic kinesin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008535803A JP2008535803A (ja) | 2008-09-04 |
| JP2008535803A5 true JP2008535803A5 (cg-RX-API-DMAC10.html) | 2009-04-16 |
Family
ID=37024314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008501920A Withdrawn JP2008535803A (ja) | 2005-03-16 | 2006-03-10 | 有糸分裂キネシン阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7625936B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1861366A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2008535803A (cg-RX-API-DMAC10.html) |
| CN (1) | CN101142183A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2006227854A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2599436A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2006101761A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2602146A1 (en) | 2005-04-07 | 2006-10-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| EP2220061B1 (en) | 2007-10-19 | 2016-02-17 | Merck Sharp & Dohme Corp. | Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity |
| PL214017B1 (pl) * | 2009-09-11 | 2013-06-28 | Univ Adama Mickiewicza | Nowe (E)-styrylo-alkinylopodstawione zwiazki krzemu oraz sposób otrzymywania (E)-styrylo-alkinylopodstawionych zwiazków krzemu |
| CN111116419B (zh) * | 2014-03-04 | 2022-03-29 | 江苏豪森药业集团有限公司 | 曲前列尼尔中间体及其制备工艺 |
| CN111138338A (zh) * | 2020-01-20 | 2020-05-12 | 中国人民解放军61699部队 | 一种光催化氟烷基吲哚啉的合成方法 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
-
2006
- 2006-03-10 JP JP2008501920A patent/JP2008535803A/ja not_active Withdrawn
- 2006-03-10 WO PCT/US2006/008482 patent/WO2006101761A2/en not_active Ceased
- 2006-03-10 US US11/886,274 patent/US7625936B2/en not_active Expired - Fee Related
- 2006-03-10 EP EP06737641A patent/EP1861366A2/en not_active Withdrawn
- 2006-03-10 CN CNA2006800081430A patent/CN101142183A/zh active Pending
- 2006-03-10 AU AU2006227854A patent/AU2006227854A1/en not_active Abandoned
- 2006-03-10 CA CA002599436A patent/CA2599436A1/en not_active Abandoned